Side-by-side · Research reference
TestagenvsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/41 cited
BFDA-ApprovedFlagship14/45 cited
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Testagen
Tirzepatide
Primary target
Testicular tissue; proposed nuclear DNA interaction
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Unknown — no HPG axis data
Glucose-dependent insulin release preserves physiological feedback
Origin
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Testagen
Tirzepatide
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
—
Frequency
Once daily or alternate days
—
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
—
Evidence basis
Animal mechanistic / in vitro onlyFedoreyeva 2011
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Route
Subcutaneous
—
Reconstitution
Sterile water or bacteriostatic saline
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Timing
—
Once weekly, any time of day
04Side Effects & Safety
Parameter
Testagen
Tirzepatide
Injection site reactions
Erythema, mild irritation (potential)
—
Systemic effects
Unknown — no human safety data
—
Hormonal impact
No published data on testosterone, LH, FSH effects
—
Long-term safety
Unknown — no long-term studies
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Pregnancy / OB
—
Contraindicated
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Testagen
- ·Active testicular malignancy
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Testagen
Tirzepatide
1. Reconstitution
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
Pen-supplied. Research vial: 27–31G insulin syringe.